Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Explore
Tags
Search
Path finder
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
irAE guide
Tumour board
Compare
Landscape grid
Rankings
Timeline
Query
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
India deep dive
China deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Complementary and supportive approaches
Hair loss and regrowth
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Completeness
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Open evaluation
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Cancers
Metastatic and recurrent anal squamous cell carcinoma
Data

Cancers·Metastatic and recurrent anal squamous cell carcinoma

DataMetastatic and recurrent anal squamous cell carcinoma

Back to the Metastatic and recurrent anal squamous cell carcinoma hub →30 connected records

Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.

Overview What it is Finding it Treating it Evidence The science Where you are Living with it What is coming Data

Data

Related pages

30

Direct links plus the targets, companies, and technologies of this cancer's products.

Similar pages

not linked directly; found by shared links

Cancer
Advanced and metastatic small bowel adenocarcinoma
Shares Paclitaxel / nab-paclitaxel, Nivolumab, PD-1, Pembrolizumab and the tags subtype-page, gastrointestinal.
Cancer
Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma
Shares PD-L1, Nivolumab, PD-1, Pembrolizumab and the tags subtype-page, gastrointestinal.
Cancer
Pancreatic acinar cell carcinoma
Shares Fluorouracil (5-FU), Robotic & minimally invasive surgery, Pembrolizumab, Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)
Shares Pembrolizumab, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.
Cancer
Borderline resectable pancreatic ductal adenocarcinoma
Shares Robotic & minimally invasive surgery, SBRT / SABR (stereotactic radiotherapy), Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
KRAS wild-type pancreatic ductal adenocarcinoma
Shares Pembrolizumab, Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.
Cancer
Locally advanced unresectable pancreatic ductal adenocarcinoma
Shares Fluorouracil (5-FU), SBRT / SABR (stereotactic radiotherapy), Cytotoxic chemotherapy and the tags subtype-page, gastrointestinal.
Cancer
BRCA or PALB2-mutant pancreatic ductal adenocarcinoma
Shares Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tags subtype-page, gastrointestinal.

technologies

6

Circulating tumour HPV DNA (ctHPV-DNA)Cytotoxic chemotherapy Immune checkpoint inhibitors Platinum agents Robotic & minimally invasive surgery SBRT / SABR (stereotactic radiotherapy)

targets

2

drugs

6

ApprovedCytotoxic chemotherapy (platinum)

ApprovedFluoropyrimidine antimetabolite

Fluorouracil (5-FU) · Adrucil / Efudex

ApprovedMonoclonal antibody (anti-PD-1)

Nivolumab · Opdivo / Opdivo Qvantig (SC)

ApprovedCytotoxic chemotherapy (taxane)

Paclitaxel / nab-paclitaxel · Taxol / Abraxane

ApprovedMonoclonal antibody (anti-PD-1)

Pembrolizumab · Keytruda / Keytruda Qlex (SC)

ApprovedAnti-PD-1 monoclonal antibody (IgG4)

Retifanlimab · Zynyz

companies

5

Bristol Myers Squibb CSPC Pharmaceutical Group Incyte Mast Therapeutics Merck & Co. (MSD)

terms

2

HPV-positive (p16) head and neck cancer Re-irradiation

trials

3

InterAACT NCI9673 POD1UM-303/InterAACT-2

key papers

6

ESMO Clinical Practice Guideline on anal cancer: diagnosis, treatment and follow-up InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer InterAACT: cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer NCI9673 part B: randomised phase 2 study of nivolumab with or without ipilimumab in refractory metastatic anal cancer NCI9673: nivolumab for previously treated unresectable metastatic anal cancer POD1UM-303/InterAACT-2: retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic anal squamous cell carcinoma

Machine-readable versions

The same record for scripts and assistants; checked 2026-09-18. Data CC BY-NC 4.0, attribute “Data from OnCo (onco.cc)”.

JSON with neighbours Markdown context RDF Turtle Sections with routes and counts API root

Not yet reviewedNeeds expert (clinical) and patient advocate review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Two rare-cancer reference links corrected to the verified… · diff · file

Wikipedia

Sources & links

InterAACT (JCO 2020)
POD1UM-303 (Lancet 2025)
Wikipedia

subtype-page gastrointestinal

Data

JSON · ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
How review works

Machine-readable versions of Metastatic and recurrent anal squamous cell carcinoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/cancers/metastatic-anal-cancer/)
Section plan: the ten sections of this record with routes, anchors and counts
All cancers as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id metastatic-anal-cancer.

WebMCP tools registered on this page: onco_search, onco_get_entity.